RxDoctor Payments Data

Stanley Patterson, MD

Family Medicine · Ventura, CANPI 1548324700

Payments from drug & device makers

$1,006in general payments, 2019–2025

Across 43 payments — averaging $23.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • Lilly USA, LLC$258
  • Gilead$127
  • AstraZeneca$85
  • Boehringer Ingelheim$70
  • AbbVie$68
  • plus $121 from 4 others

What the payments were for

  • Food & beverage$1,006100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,006 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$2,026
Medicare patients
41
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin111$129,775
OzempicSemaglutide78$83,385
FarxigaDapagliflozin Propanediol42$43,709
RybelsusSemaglutide23$40,353
TrulicityDulaglutide21$20,296
EliquisApixaban25$19,556
JanuviaSitagliptin Phosphate12$17,692
LinzessLinaclotide17$14,013
Advair HfaFluticasone Propion/Salmeterol16$6,632
Tresiba Flextouch U-100Insulin Degludec11$5,409
LevemirInsulin Detemir11$4,525
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,400
Advair DiskusFluticasone Propion/Salmeterol15$3,650
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,612
BreynaBudesonide/Formoterol Fumarate19$3,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$70$129,775111 claims
Novo NordiskOzempic, Rybelsus, Levemir$277$128,263112 claims
AstraZenecaFarxiga$85$43,70942 claims
PfizerEliquis, Premarin$26$21,54339 claims
Lilly USA, LLCTrulicity$258$20,29621 claims
MerckJanuvia$23$17,69212 claims
AbbVieLinzess$68$14,01317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Ventura

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →